Trial reportJACC. Cardiovascular interventions2023
Cause-Specific Mortality in Patients With Advanced Chronic Kidney Disease in the ISCHEMIA-CKD Trial.
Trial report in JACC. Cardiovascular interventions, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01985360 (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Chronic Kidney Disease Trial), which is not on this map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Chronic Kidney Disease Trial
Who cites it
8 citing papers in PubMed, 16 citations in OpenAlex.
- Charlson comorbidity Index for descriptive risk stratification of long-term All-cause mortality in elderly patients with acute myocardial infarction: a retrospective cohort study.Frontiers in cardiovascular medicine · 2026Article
- Pericoronary fat attenuation index on coronary CT angiography and cardiovascular risk in patients with coronary artery disease and chronic kidney disease.BMC nephrology · 2025Article
- Inflammatory and Cardiovascular Events in CKD: The Multi-Ethnic Study of Atherosclerosis (MESA).American journal of kidney diseases : the official journal of the National Kidney Foundation · 2025Observational
- Cardiovascular disease risk assessment, exercise training, and management of complications in patients with chronic kidney disease.International journal of cardiology. Cardiovascular risk and prevention · 2025Review
- Metabolic, renal, and inflammatory crosstalk in atherosclerotic cardiovascular disease: Evolving landscape and future directions.Atherosclerosis · 2025Review
- Systemic Inflammatory Response Index (SIRI) is associated with all-cause mortality and cardiovascular mortality in population with chronic kidney disease: evidence from NHANES (2001-2018).Frontiers in immunology · 2024Article
- The potential association between influenza vaccination and lower incidence of renal cell carcinoma.Clinical kidney journal · 2023Article
- ISCHEMIA-EXTEND studies: Rationale and design.American heart journal · 2022Article
Corrections and comments
- Commented on by
Authors and funding
28 authors at 18 institutions in 6 countries.
Funding
Abstract
backgroundIn ISCHEMIA-CKD, 777 patients with advanced chronic kidney disease and chronic coronary disease had similar all-cause mortality with either an initial invasive or conservative strategy (27.2% vs 27.8%, respectively).
objectivesThis prespecified secondary analysis from ISCHEMIA-CKD (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Chronic Kidney Disease) was conducted to determine whether an initial invasive strategy compared with a conservative strategy decreased the incidence of cardiovascular (CV) vs non-CV causes of death.
methodsThree-year cumulative incidences were calculated for the adjudicated cause of death. Overall and cause-specific death by treatment strategy were analyzed using Cox models adjusted for baseline covariates. The association between cause of death, risk factors, and treatment strategy were identified.
resultsA total of 192 of the 777 participants died during follow-up, including 94 (12.1%) of a CV cause, 59 (7.6%) of a non-CV cause, and 39 (5.0%) of an undetermined cause. The 3-year cumulative rates of CV death were similar between the invasive and conservative strategies (14.6% vs 12.6%, respectively; HR: 1.13, 95% CI: 0.75-1.70). Non-CV death rates were also similar between the invasive and conservative arms (8.4% and 8.2%, respectively; HR: 1.25; 95% CI: 0.75-2.09). Sudden cardiac death (46.8% of CV deaths) and infection (54.2% of non-CV deaths) were the most common cause-specific deaths and did not vary by treatment strategy.
conclusionsIn ISCHEMIA-CKD, CV death was more common than non-CV or undetermined death during the 3-year follow-up. The randomized treatment assignment did not affect the cause-specific incidences of death in participants with advanced CKD and moderate or severe myocardial ischemia. (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Chronic Kidney Disease [ISCHEMIA-CKD]; NCT01985360).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.